Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Genscript Biotech ( (HK:1548) ) just unveiled an update.
Legend Biotech, an associate of GenScript Biotech, has announced that it will present new clinical data at the 2026 American Society of Clinical Oncology Annual Meeting, underscoring its ongoing efforts in cutting-edge cancer therapies. The presentations will feature preliminary Phase 1 results for LB2102, an investigational DLL3-targeted CAR-T therapy for relapsed or refractory small-cell lung cancer and large-cell neuroendocrine carcinoma, as well as new data on its commercial CAR-T product CARVYKTI, developments that highlight the growing depth of Legend’s oncology pipeline and may influence investor perception of GenScript’s strategic exposure to innovative cell therapies.
The most recent analyst rating on (HK:1548) stock is a Buy with a HK$15.50 price target. To see the full list of analyst forecasts on Genscript Biotech stock, see the HK:1548 Stock Forecast page.
More about Genscript Biotech
GenScript Biotech Corporation, incorporated in the Cayman Islands and listed in Hong Kong, operates in the biotechnology sector. The company has an associate, Legend Biotech Corporation, which is listed on the Nasdaq Global Select Market in the U.S. and focuses on advanced cell therapies, including CAR-T treatments for oncology indications.
Average Trading Volume: 9,730,352
Technical Sentiment Signal: Sell
Current Market Cap: HK$28.49B
Find detailed analytics on 1548 stock on TipRanks’ Stock Analysis page.